Skip to main content

c-Abl [p Tyr245] Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-23313

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-23313

Key Product Details

Validated by

Biological Validation

Species Reactivity

Human, Mouse, Rat

Applications

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Phospho-c-Abl (Tyr-245) synthetic peptide (coupled to KLH) corresponding to amino acid residues around tyrosine 245 of human c-Abl. This peptide sequence has high homology to the conserved site in rat and mouse c-Abl, as well as in viral Abl and BCR-Abl fusion protein. [UniProt# P00519]

Modification

p Tyr245

Specificity

This antibody was cross-adsorbed to phospho-tyrosine coupled to agarose then affinity purified using phospho-c-Abl (Tyr-245) peptide (without carrier). On SDS-PAGE immunoblots of K-562 treated with pervanadate, the antibody detects a 145 kDa protein corresponding to c-Abl and a 210 kDa band corresponding to BCR-Abl. In addition, this antibody detects a 145 kDa band in Jurkat cells treated with pervanadate.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

145 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Description

Stable for at least 1 year at -20°C.

Scientific Data Images for c-Abl [p Tyr245] Antibody

c-Abl [p Tyr245] Antibody

Western Blot: c-Abl [p Tyr245] Antibody [NBP3-23313] -

Western Blot: c-Abl [p Tyr245] Antibody [NBP3-23313] - Western blot analysis of K-562 cells treated with pervanadate (1 mM) for 30 minutes (lanes 1, 3, & 5). Some lanes were treated with alkaline phosphatase to remove phosphorylation on c-Abl (lanes 2, 4, & 6), then the blots were probed with anti-c-Abl (lanes 1 & 2), anti-c-Abl (Tyr-412) (NBP3-23318; lanes 3 & 4), or anti-c-Abl (Tyr-245) (NBP3-23313; lanes 5 & 6).

Applications for c-Abl [p Tyr245] Antibody

Application
Recommended Usage

Western Blot

1:1000

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Formulation

PBS, 1 mg/ml BSA and 50% glycerol

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C.

Background: c-Abl

c-Abl is the human cellular homolog of a the v-Abl viral oncogene. v-Abl was originally discovered as a mouse cell-derived sequence in the genome of the Abelson murine leukemia virus (A-MuLV), a transforming retrovirus isolated by the laboratory of Dr. H.T. Abelson. c-Abl is a tyrosine kinase from the Src-family of tyrosine kinases that localizes to both the cytoplasm and nucleus. It bears an SH2 (src-homology 2) and SH3 (src-homology 3) domain responsible for mediating c-Abl protein-protein interactions. c-Abl is implicated to play a role in multiple cellular processes such as cell cycle checkpoint signaling, apoptosis, cell differentiation, cell adhesion, and transcriptional regulation. Chromosomal translocations involving the c-Abl gene are associated with human leukemias.

Long Name

Abelson Murine Leukemia Viral Oncogene Homolog 1

Alternate Names

ABL1, BCR-ABL1, bcr/abl, cAbl, JTK7

Gene Symbol

ABL1

Additional c-Abl Products

Product Documents for c-Abl [p Tyr245] Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for c-Abl [p Tyr245] Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...